See
http://www.tandfonline.com/doi/pdf/10.1080/17512433.2016.1204230
Bart
Van: Ballieux, B.E.P.B. (KCL)
Verzonden: maandag 11 juli 2016 13:33
Aan: 'chesinta'; [log in to unmask]
Onderwerp: RE: rising TSH in DCT patients on TKI's
TKI’s are Thyrosine Kinase inhibitors, like Lenvatinib, Sorafenib and vandetanib. They block VEGFreceptor- , FGFreceptor-, PDGFreceptor-, RET and
KIT signalling pathways and are used as targeted therapy for thyroid carcinoma.
Best regards,
Bart
Van: chesinta [mailto:[log in to unmask]]
Verzonden: maandag 11 juli 2016 13:25
Aan: Ballieux, B.E.P.B. (KCL)
Onderwerp: RE: rising TSH in DCT patients on TKI's
Dear Colleague,
What is TKI.
Sent from my Verizon Wireless 4G LTE smartphone
-------- Original message --------
From: Bart Ballieux
Date:07/11/2016 7:10 AM (GMT-05:00)
Subject: rising TSH in DCT patients on TKI's
Dear colleagues,
Has anyone come across marked TSH rises in iodine refractory patients with differentiated
thyroid carcinoma? This is under stable thyroxine replacement conditions.
Do TKI’s influence deiodinase activity?
Do TKI’s influence TRH-receptor signalling
Or do TKI’s possibly influence pituitary TSH-receptor signalling?
Best regards,
Bart
B.E.P.B. Ballieux PhD,
Clinical Biochemist
Endocrinology,
Department KCL, E2-P.
Leiden University Medical Centre,
P.O.box 9600,
2300RC Leiden
Tel: +3171-5262165/62278
Fax: +3171-5266753
email:
[log in to unmask]
P
Please consider the environment before printing this e-mail
------ACB discussion List Information-------- This is an open discussion list for the academic and clinical community working in clinical biochemistry. Please note, archived messages are public and can be viewed via the internet. Views
expressed are those of the individual and they are responsible for all message content. ACB Web Site
http://www.acb.org.uk Green Laboratories Work
http://www.laboratorymedicine.nhs.uk List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/